Cargando…
UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53-related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient gr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848057/ https://www.ncbi.nlm.nih.gov/pubmed/32571901 http://dx.doi.org/10.1136/jmedgenet-2020-106876 |
_version_ | 1783645047318642688 |
---|---|
author | Hanson, Helen Brady, Angela F Crawford, Gillian Eeles, Rosalind A Gibson, Sarah Jorgensen, Mette Izatt, Louise Sohaib, Aslam Tischkowitz, Marc Evans, D Gareth |
author_facet | Hanson, Helen Brady, Angela F Crawford, Gillian Eeles, Rosalind A Gibson, Sarah Jorgensen, Mette Izatt, Louise Sohaib, Aslam Tischkowitz, Marc Evans, D Gareth |
author_sort | Hanson, Helen |
collection | PubMed |
description | Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53-related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient group has been limited. To date, the only recommendation in the UK has been for annual breast MRI in women; however, more recently, a more intensive surveillance protocol including whole-body MRI (WB-MRI) has been recommended by International Expert Groups. To address the gap in surveillance for this patient group in the UK, the UK Cancer Genetics Group facilitated a 1-day consensus meeting to discuss a protocol for the UK. Using a preworkshop survey followed by structured discussion on the day, we achieved consensus for a UK surveillance protocol for TP53 carriers to be adopted by UK Clinical Genetics services. The key recommendations are for annual WB-MRI and dedicated brain MRI from birth, annual breast MRI from 20 years in women and three-four monthly abdominal ultrasound in children along with review in a dedicated clinic. |
format | Online Article Text |
id | pubmed-7848057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-78480572021-02-08 UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants Hanson, Helen Brady, Angela F Crawford, Gillian Eeles, Rosalind A Gibson, Sarah Jorgensen, Mette Izatt, Louise Sohaib, Aslam Tischkowitz, Marc Evans, D Gareth J Med Genet Position Statement Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53-related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient group has been limited. To date, the only recommendation in the UK has been for annual breast MRI in women; however, more recently, a more intensive surveillance protocol including whole-body MRI (WB-MRI) has been recommended by International Expert Groups. To address the gap in surveillance for this patient group in the UK, the UK Cancer Genetics Group facilitated a 1-day consensus meeting to discuss a protocol for the UK. Using a preworkshop survey followed by structured discussion on the day, we achieved consensus for a UK surveillance protocol for TP53 carriers to be adopted by UK Clinical Genetics services. The key recommendations are for annual WB-MRI and dedicated brain MRI from birth, annual breast MRI from 20 years in women and three-four monthly abdominal ultrasound in children along with review in a dedicated clinic. BMJ Publishing Group 2021-02 2020-06-22 /pmc/articles/PMC7848057/ /pubmed/32571901 http://dx.doi.org/10.1136/jmedgenet-2020-106876 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Position Statement Hanson, Helen Brady, Angela F Crawford, Gillian Eeles, Rosalind A Gibson, Sarah Jorgensen, Mette Izatt, Louise Sohaib, Aslam Tischkowitz, Marc Evans, D Gareth UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants |
title | UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants |
title_full | UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants |
title_fullStr | UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants |
title_full_unstemmed | UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants |
title_short | UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants |
title_sort | ukcgg consensus group guidelines for the management of patients with constitutional tp53 pathogenic variants |
topic | Position Statement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848057/ https://www.ncbi.nlm.nih.gov/pubmed/32571901 http://dx.doi.org/10.1136/jmedgenet-2020-106876 |
work_keys_str_mv | AT hansonhelen ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT bradyangelaf ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT crawfordgillian ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT eelesrosalinda ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT gibsonsarah ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT jorgensenmette ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT izattlouise ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT sohaibaslam ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT tischkowitzmarc ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT evansdgareth ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants AT ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants |